Skip to main content

Affy Shares Surge 15 Percent Despite Predicted 11-Percent Drop in Q4 Revenue

NEW YORK (GenomeWeb News) — Affymetrix today said that fourth-quarter revenue will likely fall 11.5 percent year over year, but because the company beat analysts’ estimates its shares skyrocketed.
 
Affy today said it expects total revenues for the three months ended Dec. 31, 2006, to be around $100 million compared with $111.5 million during the same period in 2005. However, analysts expected the company to post $99.5 million for the period.
 
The news caused shares in Affy to surge 15.19 percent, or $3.30, to $25.02 in mid-afternoon trading. The stock remains down more than 42 percent since this time last year.
 
Affymetrix said it will report its quarterly results after market close on Feb. 7.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.